CVR 37230634Public limited company (A/S)Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)København ØFounded 2 Nov 2015
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Clinical-Microbiomics A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
30
CVR, Aug 2026
+2 (+7.1%) over 12 months
Gross profit
13.2M
EUR, group, annual report 2025
+23.4% on 2024
Result
-1.3M
EUR, group, annual report 2025
Equity
81.2M
EUR, group, annual report 2025
Applied Industries Holding AB33.3% to under 50% of capital and votes
MANJIN ApSCVR 25379020, 5% to under 10% of capital and votes
and 3 moreOperating company
Dandex estimate: 30 employees registered in 2026Anders Christian Neto de Sousa Grønsince 1 Oct 2021
Owners of 5% or more. CVR registers shares in bands, not exact figures.
CVR 253790205% to under 10% of capital and votesclass Anotified 9 Oct 2023since 2 Nov 2015
CVR 338703455% to under 10% of capital and votesclass Anotified 9 Oct 2023since 2 Nov 2015
5% to under 10% of capital and votesclass A, B1, B2notified 1 Jul 2024since 1 Jul 2022
33.3% to under 50% of capital and votesclass Asince 9 Oct 2023
5% to under 10% of capital and votesclass A, B1 og B2notified 14 Nov 2024since 1 Jul 2024
CVR 216094985% to under 10% of capital and votesclass Anotified 9 Oct 202312 Oct 2022 to 9 Oct 2023
CVR 259953255% to under 10% of capital and votesclass Anotified 9 Oct 20232 Aug 2018 to 9 Oct 2023
CVR 285077395% to under 10% of capital and votesclass Anotified 1 Jul 20242 Aug 2018 to 1 Jul 2024
CVR 286915055% to under 10% of capital and votesclass Anotified 12 Oct 20222 Aug 2018 to 12 Oct 2022
CVR 360702425% to under 10% of capital and votesclass Anotified 9 Oct 202312 Oct 2022 to 9 Oct 2023
CVR 3673284915% to under 20% of capital and votes2 Nov 2015 to 30 Jun 2016
CVR 3723063410% to under 15% of capital and votesnotified 4 Oct 20211 Jul 2016 to 4 Oct 2021
CVR 3730659233.3% to under 50% of capital and votesnotified 24 Aug 201617 Dec 2015 to 1 Aug 2018
CVR 419694905% to under 10% of capital and votesclass Anotified 9 Oct 202329 Dec 2020 to 9 Oct 2023
CVR 426400265% to under 10% of capital and votesclass Anotified 9 Oct 20234 Oct 2021 to 9 Oct 2023
5% to under 10% of capital and votes1 Jul 2022 to 9 Oct 2023
2 Danish companies.
SubsidiaryCVR 36036869100% of capital and votes
SubsidiaryCVR 36070374100% of capital and votes
Danish companies held at 5% or more, from the CVR owner register (ejerregister), and their holdings one level down. Foreign holdings are not in CVR. Subsidiary (datterselskab): 50% or more of the votes, a Dandex estimate; in the 50% band a joint venture is not ruled out.
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Founded 2 Nov 2015.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Aug 2026, monthly: 30 employees, 26 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Jan 2016 | Feb 2016 | Mar 2016 | Apr 2016 | May 2016 | Jun 2016 | Jul 2016 | Aug 2016 | Sep 2016 | Oct 2016 | Nov 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Sep 2017 | Oct 2017 | Nov 2017 | Dec 2017 | Jan 2018 | Feb 2018 | Mar 2018 | Apr 2018 | May 2018 | Jun 2018 | Jul 2018 | Aug 2018 | Sep 2018 | Oct 2018 | Nov 2018 | Dec 2018 | Jan 2019 | Feb 2019 | Mar 2019 | Apr 2019 | May 2019 | Jun 2019 | Jul 2019 | Aug 2019 | Sep 2019 | Oct 2019 | Nov 2019 | Dec 2019 | Jan 2020 | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 | Mar 2021 | Apr 2021 | May 2021 | Jun 2021 | Jul 2021 | Aug 2021 | Sep 2021 | Oct 2021 | Nov 2021 | Dec 2021 | Jan 2022 | Feb 2022 | Mar 2022 | Apr 2022 | May 2022 | Jun 2022 | Jul 2022 | Aug 2022 | Sep 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 | Jul 2023 | Aug 2023 | Sep 2023 | Oct 2023 | Nov 2023 | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 2 | 3 | 6 | 6 | 7 | 8 | 7 | 8 | 9 | 8 | 8 | 8 | 8 | 10 | 10 | 10 | 11 | 11 | 11 | 12 | 16 | 14 | 15 | 14 | 12 | 12 | 11 | 13 | 13 | 13 | 12 | 13 | 15 | 15 | 17 | 19 | 19 | 20 | 21 | 21 | 21 | 20 | 19 | 22 | 23 | 23 | 25 | 27 | 25 | 25 | 25 | 25 | 25 | 24 | 24 | 24 | 25 | 28 | 29 | 31 | 30 | 31 | 30 | 31 | 31 | 34 | 35 | 32 | 33 | 35 | 35 | 36 | 36 | 33 | 35 | 36 | 36 | 38 | 36 | 36 | 36 | 36 | 38 | 41 | 42 | 44 | 44 | 43 | 43 | 43 | 44 | 40 | 39 | 38 | 37 | 37 | 36 | 36 | 37 | 37 | 37 | 38 | 36 | 37 | 37 | 36 | 35 | 34 | 33 | 32 | 31 | 31 | 32 | 30 | 29 | 28 | 29 | 31 | 32 | 32 | 32 | 33 | 30 | 30 | 30 | 31 | 32 | 30 |
| FTE | 2 | 2 | 4 | 4 | 4 | 6 | 6 | 6 | 7 | 6 | 7 | 7 | 7 | 8 | 8 | 8 | 9 | 9 | 8 | 9 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 10 | 10 | 10 | 10 | 11 | 11 | 12 | 14 | 13 | 14 | 14 | 15 | 15 | 14 | 14 | 16 | 18 | 16 | 19 | 21 | 19 | 20 | 19 | 19 | 20 | 19 | 19 | 19 | 19 | 20 | 21 | 23 | 21 | 21 | 23 | 25 | 25 | 26 | 28 | 27 | 27 | 30 | 30 | 30 | 31 | 29 | 30 | 32 | 31 | 32 | 32 | 33 | 33 | 33 | 34 | 36 | 37 | 40 | 39 | 39 | 39 | 38 | 38 | 37 | 34 | 34 | 34 | 34 | 33 | 33 | 33 | 33 | 33 | 34 | 34 | 34 | 35 | 34 | 33 | 32 | 31 | 30 | 29 | 29 | 29 | 27 | 27 | 25 | 25 | 26 | 28 | 28 | 28 | 28 | 26 | 27 | 27 | 27 | 27 | 26 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group. CVR changed its monthly method in Oct 2019: a step there need not be real.
Source: CVR, latest Aug 2026, published 21 Oct 2026.
Group figures (koncern) for 2023 to 2025, the company's own for 2021 and 2022, each year in its report's currency, from the annual reports filed in XBRL.
| Thousands | 2021 | 2022 | 2023group | 2024group | 2025group |
|---|---|---|---|---|---|
| Gross profit | 16,769 | 18,987 | 6,221 | 10,672 | 13,170 |
| Operating profit | -1,368 | -5,594 | -2,313 | -7,280 | -6,313 |
| Result for the year | -1,723 | -6,909 | -2,542 | -9,137 | -1,253 |
| Equity | 2,826 | 119,543 | 85,160 | 82,452 | 81,151 |
| Total assets | 28,266 | 141,635 | 102,905 | 100,950 | 93,501 |
| Employees (average) | 26 | 32 | 82 | 106 | 115 |
| Credit metrics (Dandex calculations) | |||||
| Gross profit growth (vækst i bruttofortjeneste) | -8.7% | 13.2% | 125.4% | 64.9% | 23.4% |
| EBITDA | -37 | -4,091 | 878 | 1,347 | 2,590 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Employee growth (vækst i antal ansatte) | 36.8% | 23.1% | 90.7% | 29.3% | 8.5% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex (investeringer i anlægsaktiver) | 4,280note 1 | 3,805note 1 | 82,481note 1 | 2,682 | 1,819 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for Clinical-Microbiomics A/S:
Have Pro? Sign in.
Amounts in DKK. Cash price is per DKK 1 of nominal capital, which a share split does not move. Implied value is the whole capital after the step at its cash price, not a valuation.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseCashPaid in 13,696, cash price 9.79, implied value 20,813,564 | 9.79 | 13,696 | 20,813,564 | 2,126,111 | |
| IncreaseCashPaid in 152,148, cash price 9.79, implied value 20,799,868 | 9.79 | 152,148 | 20,799,868 | 2,124,712 | |
| IncreaseCashPaid in 30,232,179, cash price 459.55, implied value 969,261,480 | 459.55 | 30,232,179 | 969,261,480 | 2,109,170 | |
| IncreaseContribution in kindPaid in 14,903,721 | None | 14,903,721 | None | 2,043,383 | |
| IncreaseA controlling stake in another companyPaid in 531,454,907 | None | 531,454,907 | None | 2,010,929 | |
| IncreaseA controlling stake in another companyPaid in 72,892,767 | None | 72,892,767 | None | 1,037,614 | |
| IncreaseCashPaid in 52,098,275, cash price 365.65, implied value 309,624,229 | 365.65 | 52,098,275 | 309,624,229 | 846,782 | |
| IncreaseCashPaid in 1,999,995, cash price 9.79, implied value 6,894,745 | 9.79 | 1,999,995 | 6,894,745 | 704,300 |
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseBonus issue from reserves | None | None | None | 500,000 | |
| IncreaseCashPaid in 3,000,000, cash price 215.98, implied value 13,799,135 | 215.98 | 3,000,000 | 13,799,135 | 63,890 | |
| FoundingCashPaid in 50,000 | None | 50,000 | None | 50,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Source: CVR, read 18 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 18 Nov 2026.
34 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Vedtægter ændret: 24.06.2025
Nyt binavn: Cmbio A/S
Til Erhvervsstyrelsens registrering af den 01.03.2024:
Kapitalforhøjelsen er besluttet den 01.03.2024.
kr. 32.454,00, blev indbetalt ved indskud af bestemmende kapitalpost, kurs 45.922,60.
Kapitalen udgør herefter kr. 2.043.393,00.
Vedtægter ændret: 30.12.2024
Vedtægter ændret: 08.11.2024
Kapitalforhøjelsen er besluttet den 08.11.2024.
kr. 1.399,00, indbetalt kontant, kurs 978,95.
Kapitalen udgør herefter kr. 2.126.111,00.
Vedtægter ændret: 27.06.2024
Vedtægter ændret: 18.06.2024
Kapitalforhøjelsen er besluttet den 18.06.2024.
kr. 15.542,00, indbetalt kontant, kurs 978,95.
Kapitalen udgør herefter kr. 2.124.712,00.
Vedtægter ændret: 07.06.2024
Kapitalforhøjelsen er besluttet den 07.06.2024.
kr. 65.787,00, indbetalt kontant, kurs 45.954,64.
Kapitalen udgør herefter kr. 2.109.170,00.
Vedtægter ændret: 01.03.2024
Kapitalforhøjelsen er besluttet den 01.03.2024.
kr. 32.454,00, indbetalt i værdier, kurs 45.922,60.
Kapitalen udgør herefter kr. 2.043.383,00.
Vedtægter ændret: 15.01.2024
Vedtægter ændret: 09.10.2023
Kapitalforhøjelsen er besluttet den 09.10.2023.
kr. 973.315,00, indbetalt ved indskud af bestemmende kapitalpost, kurs 54.602,56.
Kapitalen udgør herefter kr. 2.010.929,00.
Bestyrelse:
Fratrådte:
Thomas Alsbjerg, den 09.10.2023, Henrik Dalbøge, den 09.10.2023, Morten Otto Alexander Sommer, (formand), den 09.10.2023, Torben Thomasen, den 09.10.2023, Rasmus Vendler Toft-Kehler, den 09.10.2023.
Tiltrådte:
Morten Otto Alexander Sommer, den 09.10.2023, Bruce Harvey Grant, den 09.10.2023, Manoj Nirmal Dadlani, (formand), den 09.10.2023, Nathan Allen Ledeboer, den 09.10.2023.
Selskabet tegnes af den administrerende direktør og et bestyrelsesmedlem eller af to bestyrelsesmedlemmer i forening.
Vedtægter ændret: 12.10.2022
Kapitalforhøjelsen er besluttet den 12.10.2022.
kr. 190.832,00, indbetalt ved indskud af bestemmende kapitalpost, kurs 38.197,35.
Kapitalen udgør herefter kr. 1.037.614,00.
Bestyrelse:
Tiltrådte:
Torben Thomasen, den 12.10.2022.
Vedtægterne er yderligere ændret
Vedtægter ændret: 01.07.2022
Kapitalforhøjelsen er besluttet den 01.07.2022.
kr. 136.333,00, indbetalt kontant, kurs 38.196,47.
Kapitalen udgør herefter kr. 846.782,00.
Kapitalen er opdelt i klasser.
Vedtægter ændret: 01.07.2022
Kapitalforhøjelsen er besluttet den 01.07.2022.
kr. 1.447,00, indbetalt kontant, kurs 110,00. kr. 361,00, indbetalt kontant, kurs 978,95. kr. 723,00, indbetalt kontant, kurs 1.076,84. kr. 2.895,00, indbetalt kontant, kurs 110,00. kr. 723,00, indbetalt kontant, kurs 1.076,84.
Kapitalen udgør herefter kr. 710.449,00.
Vedtægter ændret: 24.06.2022
Vedtægter ændret: 20.12.2021
Direktion:
Fratrådte:
Martin Andreas Santini, (adm. dir), den 30.09.2021.
Tiltrådte:
Anders Christian Neto de Sousa Grøn, (adm. dir), den 01.10.2021.
Bestyrelse:
Fratrådte:
Morten Asser Karsdal, den 28.06.2021.
Bestyrelse:
Fratrådte:
Ole Skov, den 08.06.2021.
Bestyrelse:
Fratrådte:
Dennis Landbo Nielsen, den 28.01.2021.
Tiltrådte:
Thomas Alsbjerg, den 28.01.2021, Ole Skov, den 28.01.2021.
Ny adresse: Fruebjergvej 3, 2100 København Ø
Vedtægter ændret: 31.01.2020
Vedtægterne er yderligere ændret
Vedtægter ændret: 31.10.2019
Vedtægter ændret: 31.10.2019
Bestyrelse:
Fratrådte:
Ole Skov (formand), den 29.10.2017, Morten Otto Alexander Sommer, den 29.10.2017.
Tiltrådte:
Morten Otto Alexander Sommer (formand), den 29.10.2017.
Vedtægter ændret: 26.06.2017
Vedtægter ændret: 24.08.2016
Kapitalforhøjelsen er besluttet den 24.08.2016.
kr. 204.300,00, indbetalt kontant, kurs 978,95.
Kapitalen udgør herefter kr. 704.300,00.
Bestyrelse:
Tiltrådte:
Henrik Dalbøge, den 24.08.2016.
Direktion:
Fratrådte:
Lone Merete Veng (adm. dir), den 01.06.2016.
Tiltrådte:
Martin Andreas Santini (adm. dir), den 01.06.2016.
Ny adresse: Ole Maaløes Vej 3, 2200 København N
Ny kommune: København
Revision:
Fratrådte:
RSM P/S STATSAUTORISEREDE REVISORER, den 04.07.2016.
Tiltrådte:
CVR-NR. 32895468 BEIERHOLM, STATSAUTORISERET REVISIONSPARTNERSELSKAB, Ellebjergvej 52, 2450 København SV, den 04.07.2016.
Virksomheden er omdannet til et aktieselskab med CVR-nummer: 37230634 Vedtægter ændret: 04.04.2016
Nyt navn: Clinical-Microbiomics A/S
Kapitalforhøjelse: kr. 436.110,00, indbetalt ved overførte reserver / overskud, kurs 100,00.
Ledelsen har erklæret sig for værdier i forbindelse med kapitalforhøjelsen.
Kapitalen udgør herefter kr. 500.000,00.
Bestyrelse:
Fratrådte:
.
Direktion:
Fratrådte:
Morten Otto Alexander Sommer, den 01.01.2016, Rasmus Vendler Toft-Kehler, den 01.01.2016.
Tiltrådte:
Lone Merete Veng (adm. dir), den 01.01.2016.
Vedtægter ændret: 16.12.2015
Kapitalforhøjelse: kr. 13.890,00, indbetalt kontant, kurs 21.598,27.
Kapitalen udgør herefter kr. 63.890,00.
Bestyrelse:
Tiltrådte:
Dennis Landbo Nielsen, den 16.12.2015, Ole Skov (formand), den 16.12.2015, Morten Otto Alexander Sommer, den 16.12.2015, Rasmus Vendler Toft-Kehler, den 16.12.2015.
Selskabet tegnes af bestyrelsens formand i forening med et bestyrelsesmedlem eller en direktør..
Stiftelsesdato: 02.11.2015.
Virkningsdato: 02.11.2015.
Seneste vedtægtsdato: 02.11.2015.
Kapital:
kr. 50.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 50.000,00 til kurs 100,00, fuldt indbetalt.
Stiftere:
CVR-NR. 25379020 MANJIN ApS, c/o Morten Sommer, Parsbergsvej 40, 2830 Virum, den 02.11.2015, CVR-NR. 33870345 VENDLER ApS, c/o Rasmus Vendler Tof, Wilhelm Marstrands Gade 22, 2100 København Ø, den 02.11.2015.
Direktion:
Morten Otto Alexander Sommer, den 02.11.2015, Rasmus Vendler Toft-Kehler, den 02.11.2015.
Selskabet tegnes af to direktører i forening..
Revision:
CVR-NR. 34713022 RSM PLUS P/S STATSAUTORISEREDE REVISORER, Ellebjergvej 52, 2., 2450 København SV, den 02.11.2015.
Første regnskabsår:
02.11.2015 - 31.12.2016.
Regnskabsår:
01.01 - 31.12.
Formål:
Selskabets formål er at drive kontraktsforskning inden for bioteknologi samt hermed beslægtede aktiviteter.
P-number 1029207182Bygstubben 9, 2950 Vedbæk
P-number 1020898778Fruebjergvej 3, 2100 København Ø
P-number 1029207166Bygstubben 9, 2950 Vedbæk
No other current company drawn.
No other current company drawn.
No other current company drawn.
No other current company drawn.